Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver

Saleh Alqahtani, Paolo Federico and Robert P. Myers
CMAJ September 11, 2007 177 (6) 568-569; DOI: https://doi.org/10.1503/cmaj.061272
Saleh Alqahtani MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Federico MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert P. Myers MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Carnitene in the treatment of valproic acid hyperammonemia
    Adriano M Pellicelli
    Posted on: 28 November 2007
  • Possible new clinical sign of hyperammonemia
    Harold A Pupko
    Posted on: 17 September 2007
  • Posted on: (28 November 2007)
    Page navigation anchor for Carnitene in the treatment of valproic acid hyperammonemia
    Carnitene in the treatment of valproic acid hyperammonemia
    • Adriano M Pellicelli

    The article of Alqahtani et al. describes a case of hyperammonemia due to valproic acid (VPA). Although the majority of patients who had an hyperammonaemia related to VPA are asymptomatic, we have observed patients with hyperammoniemic encephalopathy associated to stupor and coma. Valproic acid can induce alteration of metabolism of ammonia through an alteration of urea cycle. In particular VPA inhibits enzyme carbam...

    Show More

    The article of Alqahtani et al. describes a case of hyperammonemia due to valproic acid (VPA). Although the majority of patients who had an hyperammonaemia related to VPA are asymptomatic, we have observed patients with hyperammoniemic encephalopathy associated to stupor and coma. Valproic acid can induce alteration of metabolism of ammonia through an alteration of urea cycle. In particular VPA inhibits enzyme carbamyl phosphate synthetase which is the first enzyme involved in the urea cycle. Inhibition of this enzyme prevents the incorporation of ammonia in the urea. Hyperammoniemia results from greater renal production along with reduced hepatic production of urea. Furthermore VPA reduces, with a not so well elucidated mechanism, levels of carnitine especially during long term or high dose therapy. Hyperammonemia is directly associated to a considerable reduction in free serum carnitine concentration. L Carnitine depletion can further impair urea cycle resulting in accumulation of ammonia, and can cause an intracellular accumulation of toxic acyl-coa resulting in impairment in several enzymatic processes. In the case herein described, besides the suspension of VPA, it could has been usefull, for the pathogenetic mechamism at the basis of hyperammoniaemia, the administration of L carnitine. Several reports have demonstrated as L carnitine supplementation has been shown to improve and reduce the duration of symptoms due to VPA related toxicities and remove the inhibition of VPA on carbamyl phosphate synthetase and urea synthesis (1,2,3). Furthermore preventive administration of Carnitine can allow to continue receiving VPA, a medication for which there are currently few substitutes.

    References 1.Lheureux ER, Penaloza A., Zahir S., Gris M. Science review : carnitine in the treatment of valproic acid-induced toxicity-what is the evidence?. Critical Care. 2005; 9:431-440 2. Wadzinski J., Franks R., Roane D., Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007; 20:499-502 3. Raby W.N Carnitine for valproic acide induced hyperammonemia. Am J Psychiatry.1997; 154:8

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (17 September 2007)
    Page navigation anchor for Possible new clinical sign of hyperammonemia
    Possible new clinical sign of hyperammonemia
    • Harold A Pupko

    The article by Alqahtani et al is a welcome reminder that hyperammonemia is a common side effect of valproate therapy. I am not, however, convinced that hyperammonemia is a benign asymptomatic condition. I wonder whether the sedation often accepted as a side effect of valproate is indeed a symptom of low-grade encephalopathy. I have had two patients with bipolar disorder taking valproate in the past year complain of foul sm...

    Show More

    The article by Alqahtani et al is a welcome reminder that hyperammonemia is a common side effect of valproate therapy. I am not, however, convinced that hyperammonemia is a benign asymptomatic condition. I wonder whether the sedation often accepted as a side effect of valproate is indeed a symptom of low-grade encephalopathy. I have had two patients with bipolar disorder taking valproate in the past year complain of foul smelling urine. The odour was described by both as “strong,” and, on smelling it myself, I was at loss to come up with a better descriptor. Blood ammonia levels were elevated in both patients, and, since mood stabilization was sub optimal on an already optimal dose, I decided to discontinue the valproate. Both patients noted that the smell disappeared upon discontinuation of the medication and has since not returned. As well, mental clarity was subjectively felt to be improved as well. Of note, both patients were placed on oxcarbazepine instead of valproate with significant improvement in mood stability. If strong smelling urine is indeed a sign of valproate related hyperammonemia, it is simple enough to question patients as to whether they are experiencing this side effect. If they are, I would then suggest that a blood ammonia level be drawn and, if elevated, the need for this medication be reassessed. In family practice, this odour may be mistaken for a urinary tract infection. Should a negative culture come back in the absence of other clinical signs such as urgency and dysuria in a patient taking valproate, I would suspect the medication as the culprit. The authors recommendations for managing valproate related hyperammonemic encephalopathy are prudent, but I wonder if they are missing half the picture. Does valproate unmask underlying conditions such as urea cycle disorders or fatty acid oxidation defects? Were these disorders looked for in this patient, and, if not, why not? More importantly, how does the average family doctor begin investigating for these problems? What tests should the physician in the trenches be ordering to screen for these conditions once suspicions are raised? Perhaps the CMAJ could more thoroughly address this issue in a future edition. Harold Pupko M.D. Private practice Toronto

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 177 (6)
CMAJ
Vol. 177, Issue 6
11 Sep 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver
Saleh Alqahtani, Paolo Federico, Robert P. Myers
CMAJ Sep 2007, 177 (6) 568-569; DOI: 10.1503/cmaj.061272

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver
Saleh Alqahtani, Paolo Federico, Robert P. Myers
CMAJ Sep 2007, 177 (6) 568-569; DOI: 10.1503/cmaj.061272
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Carbamazepine-induced hyperammonemia
  • Possible new clinical sign of hyperammonemia
  • Possible new clinical sign of hyperammonemia
  • Google Scholar

More in this TOC Section

  • Endometrial osseous metaplasia with secondary infertility
  • Bell palsy
  • Vitamin B12 deficiency
Show more Practice

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Drugs: psychotherapeutic

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire